Clene to Present at the Emerging Growth Conference
Clene (Nasdaq: CLNN) will present a corporate update at the Emerging Growth Conference on October 23, 2025 at 3:10 p.m. ET. The company and its subsidiary Clene Nanomedicine, a clinical-stage biopharmaceutical focused on mitochondrial health and treatments for neurodegenerative diseases including ALS and MS, will deliver the virtual presentation.
A live webcast and accompanying slides will be available via the Events section of Clene's website and by registration at the provided webcast link. A replay will be posted on the conference portal and the Emerging Growth YouTube channel after the event.
Clene (Nasdaq: CLNN) presenterà un aggiornamento aziendale al Emerging Growth Conference il 23 ottobre 2025 alle 15:10 ora ET. L'azienda e sua controllata Clene Nanomedicine, una biopharmaceutical in fase clinica focalizzata sulla salute mitocondriale e sui trattamenti per malattie neurodegenerative tra cui ALS e sclerosi multipla, terranno la presentazione virtuale.
Una sessione webcast in diretta e le slide accompagnatorie saranno disponibili nella sezione Eventi del sito web di Clene e previa registrazione al link webcast fornito. Una replica sarà pubblicata sul portale della conferenza e sul canale Emerging Growth YouTube dopo l'evento.
Clene (Nasdaq: CLNN) presentará una actualización corporativa en la Emerging Growth Conference el 23 de octubre de 2025 a las 3:10 p.m. hora ET. La empresa y su filial Clene Nanomedicine, una biopharmaceutical en etapa clínica centrada en la salud mitocondrial y tratamientos para enfermedades neurodegenerativas como ALS y esclerosis múltiple, ofrecerán la presentación virtual.
Una transmisión en vivo y las diapositivas acompañantes estarán disponibles a través de la sección de Eventos del sitio web de Clene y mediante registro en el enlace de webcast proporcionado. Una repetición se publicará en el portal de la conferencia y en el canal de YouTube de Emerging Growth tras el evento.
Clene (나스닥: CLNN)은 2025년 10월 23일 동부표준시 3:10 p.m.에 열리는 Emerging Growth Conference에서 기업 업데이트를 발표합니다. 임상 단계의 생물의약품 회사인 Clene Nanomedicine은 미토콘드리얼 건강 및 ALS와 MS를 포함한 신경퇴행성 질환 치료에 초점을 맞추고 있으며, 가상 발표가 진행될 예정입니다.
라이브 웹캐스트와 동반 슬라이드는 Clene의 웹사이트의 이벤트 섹션에서 이용 가능하며 제공된 웹캐스트 링크로 등록해야 합니다. 이벤트 후에는 컨퍼런스 포털 및 Emerging Growth의 YouTube 채널에 리플레이가 게시됩니다.
Clene (Nasdaq: CLNN) présentera une mise à jour de l'entreprise lors de la Emerging Growth Conference le 23 octobre 2025 à 15h10, heure ET. L'entreprise et sa filiale Clene Nanomedicine, une biopharmaceutique en phase clinique axée sur la santé mitochondriale et les traitements des neurodégénératives, notamment la SLA et la sclérose en plaques, livreront la présentation virtuelle.
Une diffusion en direct et les diapositives associées seront disponibles via la section Événements du site Web de Clene et sur inscription au lien de webcast fourni. Un replay sera publié sur le portail de la conférence et sur la chaîne YouTube d'Emerging Growth après l'événement.
Clene (Nasdaq: CLNN) wird während der Emerging Growth Conference ein Unternehmensupdate vortragen am 23. Oktober 2025 um 15:10 Uhr ET. Das Unternehmen und seine Tochtergesellschaft Clene Nanomedicine, ein klinisch aktives Biopharmaunternehmen mit Fokus auf mitochondriale Gesundheit und Behandlungen neurodegenerativer Erkrankungen, darunter ALS und MS, wird die virtuelle Präsentation halten.
Einen Live-Webcast und begleitende Folien wird im Bereich Veranstaltungen der Clene-Website sowie durch Registrierung über den bereitgestellten Webcast-Link verfügbar sein. Eine Wiederholung wird nach der Veranstaltung im Konferenzportal und auf dem Emerging Growth YouTube-Kanal veröffentlicht.
Clene (ناسداك: CLNN) ستقدم تحديثاً للشركة في مؤتمر Emerging Growth في 23 أكتوبر 2025 الساعة 3:10 مساءً بتوقيت شرق الولايات المتحدة. ستقدم الشركة والشركة التابعة لها Clene Nanomedicine، وهي شركة أدوية حيوية في المرحلة السريرية تركز على صحة الميتوكوندريا وعلاجات للأمراض العصبية التنكسية بما في ذلك ALS والتصلب المتعدد، العرض الافتراضي.
سيكون هناك بث حي على الويب مع الشرائح المصاحبة متاحاً عبر قسم الأحداث في موقع Clene الإلكتروني وبالتسجيل على رابط البث المقدم. سيتم نشر إعادة العرض على بوابة المؤتمر وقناة Emerging Growth على YouTube بعد الحدث.
Clene（纳斯达克股票代码：CLNN） 将在 2025年10月23日美国东部时间下午3:10 于 Emerging Growth Conference 上进行公司更新。公司及其子公司 Clene Nanomedicine，一家处于临床阶段、专注于线粒体健康及神经退行性疾病治疗（包括ALS和MS）的生物制药公司，将进行线上演讲。
现场网络直播及随附幻灯片将可通过 Clene 网站的“活动”板块以及通过提供的网络直播链接进行注册获取。活动结束后，会议门户及 Emerging Growth 的 YouTube 频道将发布回放。
- None.
- None.
SALT LAKE CITY, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference.
Virtual Presentation Details
Date: October 23, 2025
Time of Presentation: 3:10 p.m. ET
Format: Corporate update
A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register for and view the webcast, along with accompanying slides, here: https://goto.webcasts.com/starthere.jsp?ei=1717092&tp_key=1ddfafa563&sti=clnn. A replay of the presentation will also be available through the conference portal and the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference, following the event.
About the Emerging Growth Conference
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.
The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.
All sessions will be conducted through video webcasts and will take place in the Eastern time zone.
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
Investor Contact
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
617-283-2856
FAQ
When will Clene (CLNN) present at the Emerging Growth Conference?
How can investors watch the Clene (CLNN) Emerging Growth Conference presentation?
Will a replay of the Clene (CLNN) presentation be available after October 23, 2025?
What topics will Clene (CLNN) cover in the October 23, 2025 presentation?
What is Clene Nanomedicine's clinical focus mentioned in the presentation notice?
